• Aprotinin (BPTI) in Translational Research: Mechanisms, Impa

  2026-07-09

  This thought-leadership article explores the mechanistic underpinnings and translational strategies surrounding Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI), with a focus on its role in serine protease inhibition, perioperative blood loss reduction, and inflammation modulation. Bridging evidence from cardiovascular surgery research and advanced transcriptomic workflows, it offers protocol guidance and competitive insights for translational researchers poised to exploit Aprotinin’s unique biochemical properties in complex experimental systems.

• BCECF in Microenvironmental pH Regulation: Principles to Pre

  2026-07-08

  Explore how BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) enables advanced, quantitative analysis of extracellular pH microenvironments in biomedical research. This in-depth guide reveals unique methodological insights and practical assay strategies distinct from existing resources.

• Bleomycin Sulfate: Protocols and Pitfalls for Pulmonary Fibr

  2026-07-08

  Bleomycin Sulfate is a DNA strand break inducer widely used to model chemotherapy-induced DNA damage and pulmonary fibrosis, especially for mechanistic studies involving TGF-β/Smad and JAK-STAT signaling pathways. This article details protocol parameters, solubility considerations, and workflow best practices to optimize reproducibility in both in vitro and in vivo settings. Avoid use where precise long-term solution stability or ethanol solubility is required.

• Bromodomain Inhibitor (+)-JQ1: Multi-Pathway Modulation & Pr

  2026-07-07

  Explore the multi-dimensional impact of Bromodomain Inhibitor, (+)-JQ1 on chromatin regulation, apoptosis, and cytokine storm modulation. This article uniquely integrates mechanistic insights, protocol parameters, and assay guidance for advanced BET bromodomain inhibitor research.

• Amitriptyline HCl in High-Throughput BBB & Neuropharmacology

  2026-07-07

  Amitriptyline HCl empowers rigorous in vitro blood-brain barrier (BBB) and receptor modulation assays, enabling nuanced CNS drug discovery workflows. This workflow-focused review highlights key innovations, protocol optimizations, and troubleshooting strategies to maximize translational impact with this APExBIO tricyclic research compound.

• Dasatinib (BMS-354825): Optimizing Kinase Assays in Cancer M

  2026-07-06

  Dasatinib (BMS-354825) unlocks precise, multi-kinase targeting for advanced oncology workflows, enabling researchers to dissect Src and Bcr-Abl signaling in both cellular and animal systems. Leveraging recent breakthroughs in EMT and stemness mechanisms, this guide translates cutting-edge insights into robust experimental protocols and troubleshooting strategies.

• Macrophage-Derived EV miR-660 Drives Breast Cancer Metastasi

  2026-07-06

  This study uncovers how tumor-associated macrophage (TAM)-derived extracellular vesicles (EVs) transfer microRNA-660 to breast cancer cells, promoting metastasis via suppression of KLHL21 and activation of the IKKβ/NF-κB p65 pathway. The findings highlight a critical non-cell-autonomous mechanism in breast cancer progression and suggest new avenues for targeting TAM-EV-miRNA interactions.

• Sex Differences in Cannabinoid Withdrawal Revealed by WIN 55

  2026-07-05

  Brewer et al. systematically investigated somatic and anxiety-like withdrawal behaviors in male and female rats following exposure to the synthetic cannabinoid agonist WIN 55,212-2. Their findings uncover distinct sex-specific behavioral signatures during withdrawal, with implications for endocannabinoid system modulator research and preclinical modeling of cannabinoid dependence.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Tumo

  2026-07-04

  This article reviews the preclinical characterization of anlotinib hydrochloride as a highly potent and selective vascular endothelial growth factor receptor-2 (VEGFR2) inhibitor. The study establishes its robust anti-angiogenic mechanism, strong selectivity profile, and in vivo efficacy, providing a foundation for its use in cancer research and translational workflows.

• Reliable CaMKII Inhibition with KN-62, 1-[N,O-bis-(5-isoquin

  2026-07-03

  This article addresses common laboratory challenges in cell signaling and proliferation assays, demonstrating how KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine (SKU A8180) delivers selective, reproducible inhibition of CaMKII for robust experimental outcomes. Grounded in literature and vendor transparency, it provides evidence-driven guidance on protocol design, data interpretation, and product selection for biomedical researchers.

• AR Heterogeneity Drives Divergent Prostate Cancer Therapy Re

  2026-07-03

  This study reveals that androgen receptor (AR) expression in prostate cancer is highly heterogeneous, delineating distinct cellular subtypes with different responses to castration and enzalutamide. By modeling AR+/hi and AR−/lo clones, the research provides evidence for tailored therapeutic strategies and highlights BCL-2 as a promising target in resistant disease.

• Podophyllotoxin in HCC: Mechanistic Insights and Experimenta

  2026-07-02

  Explore how Podophyllotoxin, a key cell cycle arrest agent, advances hepatocellular carcinoma (HCC) research. This article delivers unique, protocol-driven insights and comparative analysis to optimize your assays.

• FLT3–TAZ Axis Drives Drug Resistance in Blast Phase CML

  2026-07-02

  Shin et al. reveal that aberrant FLT3 signaling, via JAK–STAT3–TAZ–TEAD–CD36, underlies drug resistance and poor prognosis in blast phase chronic myeloid leukemia (BP-CML). The study leverages multi-omics and patient-derived models to propose FLT3 as both a prognostic marker and therapeutic target, advancing strategies for overcoming tyrosine kinase inhibitor resistance.

• MK-4827 (Niraparib): Optimizing PARP Inhibition in Cancer Re

  2026-07-01

  MK-4827 (Niraparib) from APExBIO enables precise and potent PARP-1/-2 inhibition, accelerating BRCA-mutant and combination strategy cancer research. Recent studies reveal that hyperthermia-induced modulation of DNA repair enhances its impact even in BRCA2-proficient models, providing a new dimension to experimental design.

• Asunaprevir (BMS-650032): Strategic Horizons in HCV Research

  2026-07-01

  This thought-leadership article explores the mechanistic, translational, and strategic value of Asunaprevir (BMS-650032) for hepatitis C virus research. We dissect its structure-function insights, experimental best practices, and competitive edge, while bridging recent advances in chromatin-targeted oncology as a conceptual lens for next-generation antiviral strategies. This piece advances the discussion beyond standard protocols, offering actionable guidance for translational scientists and research leaders.

14678 records 1/979 page Next 12345 下5页 Last page